EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Rifaximin Plus Probiotics Reshape Gut Microbiota, Serum Propionate, and Mucosal Immunity in Cirrhosis‐Related Hepatic Encephalopathy Microbiota‐Immune Remodeling in HE

Yiping Wang iD, Hui Zhu, Shujun Wang, Danni Hu, Mengdan Xu, Luna Lee, Dylan Lee iD

Canadian Journal of Gastroenterology and Hepatology · 2026-01 · 2026 (1)

DOI: 10.1155/cjgh/2389961 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 13.07.2026. Verfasst von Yiping Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Cixi Hospital, Wenzhou Medical University, Cixi, Zhejiang, 315300, China, wmu.edu.cn. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Gastrointestinal Microbiome, Hepatic Encephalopathy, Immunity, Mucosal. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: One clinical specialty construction program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatic encephalopathy (HE) remains a major cause of hospitalization and readmission in cirrhosis and is closely linked to hyperammonemia, microbial dysbiosis, impaired short‐chain fatty acid (SCFA) output, barrier dysfunction, and altered mucosal immunity. We evaluated whether adding a multistrain probiotic to rifaximin was associated with greater neurometabolic improvement and coordinated gut–liver–brain axis changes.

Methods

In this prospective, 6‐month, randomized, open‐label, assessor‐blinded, three‐arm controlled study, 61 adults with cirrhosis‐related HE received standard care alone (Con, n = 20), standard care plus rifaximin 550 mg twice daily (Rif, n = 20), or rifaximin plus a multistrain probiotic (1 × 10^9 CFU three times daily; Rif + Pro, n = 21). The main prespecified biochemical readout was serum ammonia at Month 6. A composite HE index incorporating mental status, flapping tremor, number connection test, and ammonia grade was analyzed as a prespecified exploratory neurometabolic score. A predefined mechanistic subset underwent 16S rRNA microbiome profiling, serum SCFA measurement, and fecal secretory IgA (SIgA) testing.

Results

Baseline characteristics did not differ across arms. Post‐treatment serum ammonia decreased in a graded pattern (Con 177 ± 43.2, Rif 143 ± 37.5, Rif + Pro 117 ± 34.3 μmol/L), with parallel improvement in the exploratory HE index (10.0 ± 4.9, 5.3 ± 4.7, and 3.7 ± 4.1, respectively). In the mechanistic subset, the microbial community structure differed by treatment (PERMANOVA p = 0.006). Rif + Pro was associated with higher serum propionate, increased Lactobacillus salivarius–associated signal, reduced Bacteroides ovatus–associated signal, and marked fecal SIgA elevation compared with standard care or rifaximin alone. The SIgA–propionate relationship was interpreted as exploratory.

Conclusions

Rifaximin plus multistrain probiotics was associated with greater improvement in serum ammonia and exploratory HE severity readouts than rifaximin alone, accompanied by coordinated microbial, metabolic, and mucosal immune changes. These findings support confirmation in adequately powered event‐driven trials with strain‐resolved profiling and targeted metabolomics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsGastrointestinal MicrobiomeHepatic EncephalopathyImmunity, MucosalLiver CirrhosisProbioticsRifaximinAgedFemaleHumansMaleMiddle AgedAmmoniaFatty Acids, VolatilePropionatesProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

hepatic encephalopathymicrobiotasecretory IgAshort-chain fatty acid

Substanzen

AmmoniaFatty Acids, VolatileGastrointestinal AgentsPropionatesRifaximin

Autor:innen und Institutionen

  • Department of Gastroenterology, Affiliated Cixi Hospital, Wenzhou Medical University, Cixi, Zhejiang, 315300, China, wmu.edu.cn.
  • Family Medicine, Axess Family Services, Inc., Ravenna, Ohio, 44226, USA.
  • Internal Medicine, CuraStrategix Health, Cleveland, Ohio, 44202, USA.

ORCID-Profile: Yiping Wang, Dylan Lee

Förderung

  • One clinical specialty construction program

Zitieren

APA

Wang, Y., Zhu, H., Wang, S., Hu, D., Xu, M., Lee, L., & Lee, D. (2026). Rifaximin Plus Probiotics Reshape Gut Microbiota, Serum Propionate, and Mucosal Immunity in Cirrhosis‐Related Hepatic Encephalopathy Microbiota‐Immune Remodeling in HE. Canadian Journal of Gastroenterology and Hepatology, 2026(1). https://doi.org/10.1155/cjgh/2389961

Vancouver

Wang Y, Zhu H, Wang S, Hu D, Xu M, Lee L, et al. Rifaximin Plus Probiotics Reshape Gut Microbiota, Serum Propionate, and Mucosal Immunity in Cirrhosis‐Related Hepatic Encephalopathy Microbiota‐Immune Remodeling in HE. Canadian Journal of Gastroenterology and Hepatology. 2026;2026(1). doi:10.1155/cjgh/2389961

BibTeX
@article{Wang2026,
  author = {Wang, Yiping and Zhu, Hui and Wang, Shujun and Hu, Danni and Xu, Mengdan and Lee, Luna and Lee, Dylan},
  title = {Rifaximin Plus Probiotics Reshape Gut Microbiota, Serum Propionate, and Mucosal Immunity in Cirrhosis‐Related Hepatic Encephalopathy Microbiota‐Immune Remodeling in HE},
  journal = {Canadian Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cjgh/2389961}
}
Kostenlos starten →